Product Information
CARBIDOPA-LEVO ER 61.25-245 CP is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $3.9279 per EA under NDC 70710214201. Its NADAC has been published 33 times since Feb 18, 2026.
FDA first approved this application on Jan 7, 2015.
The High Outlier badge above means this manufacturer's average price in the Carbidopa and Levodopa market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
61.25; 245 mg/1; mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
70710214201
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBIDOPA; LEVODOPAApproval Type
Authorized Generic (NDA)
FDA Application
NDA203312FDA Approved
1/7/2015
On Market Since
10/20/2025
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVO ER 61.25-245 CP has been published 33 times since Feb 18, 2026, and over the history we have for it it has risen 4.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.9279 per EA |
|---|---|
| All-time high | $3.9279 (Sep 30, 2026) |
| All-time low | $3.7464 (Apr 22, 2026) |
| 52-week high | $3.9279 |
| 52-week low | $3.7464 |
| Median price | $3.7776 |
| Average price | $3.7978 |
| Largest weekly change | +1.6% (Jul 22, 2026) |
| Weeks tracked | 33 |
| Tracking since | Feb 18, 2026 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 11% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Carbidopa and Levodopa market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatic Amino Acid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVO ER 61.25-245 CP?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVO ER 61.25-245 CP, manufactured by Zydus Pharmaceuticals (USA) Inc., is $3.9279 per EA (NDC 70710214201), effective Sep 30, 2026.
How has the price of CARBIDOPA-LEVO ER 61.25-245 CP changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVO ER 61.25-245 CP has risen 4.0%. It has been tracked across 33 weekly CMS publications since Feb 18, 2026.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVO ER 61.25-245 CP?
Since Feb 18, 2026, the NADAC for CARBIDOPA-LEVO ER 61.25-245 CP has ranged from a low of $3.7464 (Apr 22, 2026) to a high of $3.9279 (Sep 30, 2026), with a median of $3.7776 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVO ER 61.25-245 CP?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RYTARY ER 61.25 MG-245 MG CAP, is $3.5009 per EA — about 11% below CARBIDOPA-LEVO ER 61.25-245 CP.
Who manufactures CARBIDOPA-LEVO ER 61.25-245 CP?
CARBIDOPA-LEVO ER 61.25-245 CP (NDC 70710214201) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.